Hedyeh Ebrahimi, MD, MPH, discusses updated data from a phase 1 study of CBM588, cabozantinib, and nivolumab in metastatic renal cell carcinoma.

The FDA approved agents in MIBC and neuroendocrine tumors and amivantamab/lazertinib continues to shine in NSCLC.

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...

The GI Cancers Symposium revealed new therapies for specific cancer subsets and progress in chimeric antigen receptor T-cell ...

Matt Galsky, MD, discusses the phase 3 NIAGARA trial that led to the recent FDA approval of durvalumab in muscle-invasive ...

Experts discuss clinical experience with established and emerging treatment approaches in diffuse large B-cell lymphoma ...

Uday R. Popat, MD, discusses promising findings from a phase 2 trial evaluating the JAK inhibitor itacitinib combined with ...

The primary end point of overall response rate has been met in the COMPANION-002 trial of tovecimig and paclitaxel in ...

Akriti Jain, MD, discussed how emerging data on non-ABL1 mutations is reshaping chronic myeloid leukemia management.

Deborah Wong, MD, PhD, discusses the toripalimab combination that is now considered standard of care in nasopharyngeal cancer ...

During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic ...

Enriqueta Felip, MD, PhD, discusses the phase 3 3475A-D77 study of subcutaneous pembrolizumab plus chemotherapy in metastatic non–small cell lung cancer.